CANCER:

Waldenstrom Macroglobulinemia

Related cancers:

‹

›

No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval	zanubrutinib Sensitive: A1 - Approval
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ibrutinib Sensitive: A1 - Approval	rituximab + ibrutinib Sensitive: A1 - Approval
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: A1 - Approval	ibrutinib Sensitive: A1 - Approval
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	acalabrutinib Sensitive: A2 - Guideline	acalabrutinib Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: A2 - Guideline	rituximab + ixazomib Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	fludarabine oral Sensitive: A2 - Guideline	fludarabine oral Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab Sensitive: A2 - Guideline	rituximab Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	cladribine Sensitive: A2 - Guideline	cladribine Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + bortezomib Sensitive: A2 - Guideline	rituximab + bortezomib Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	everolimus Sensitive: A2 - Guideline	everolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	bortezomib Sensitive: A2 - Guideline	bortezomib Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ofatumumab Sensitive: A2 - Guideline	ofatumumab Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + carfilzomib + dexamethasone Sensitive: A2 - Guideline	rituximab + carfilzomib + dexamethasone Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	R-CHOP Sensitive: A2 - Guideline	R-CHOP Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	IRd Sensitive: A2 - Guideline	IRd Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	FCR Sensitive: A2 - Guideline	FCR Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	bortezomib + dexamethasone Sensitive: A2 - Guideline	bortezomib + dexamethasone Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	bendamustine Sensitive: A2 - Guideline	bendamustine Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	BDR Sensitive: A2 - Guideline	BDR Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	BR Sensitive: A2 - Guideline	BR Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CaRD Sensitive: A2 - Guideline	CaRD Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	RCD Sensitive: A2 - Guideline	RCD Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	RCP Sensitive: A2 - Guideline	RCP Sensitive: A2 - Guideline
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CLR 131 Sensitive: B - Late Trials	CLR 131 Sensitive: B - Late Trials
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials	zanubrutinib Sensitive: B - Late Trials
MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C2 – Inclusion Criteria	ibrutinib Sensitive: C2 – Inclusion Criteria
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C2 – Inclusion Criteria Blood Adv - 3 weeks	ibrutinib Sensitive: C2 – Inclusion Criteria Blood Adv - 3 weeks
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
MYD88 mutation + CXCR4 mutation MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation + CXCR4 mutation MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C2 – Inclusion Criteria	ibrutinib Sensitive: C2 – Inclusion Criteria
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	BDR Sensitive: C3 – Early Trials	BDR Sensitive: C3 – Early Trials
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + carfilzomib Sensitive: C3 – Early Trials	rituximab + carfilzomib Sensitive: C3 – Early Trials
CXCR4 G336X CXCR4 G336X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 G336X CXCR4 G336X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 S338X CXCR4 S338X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 S338X CXCR4 S338X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 H350fs* CXCR4 H350fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 H350fs* CXCR4 H350fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 S338X + TP53 R196X CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 S338X + TP53 R196X CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 K327fs* CXCR4 K327fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 K327fs* CXCR4 K327fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 R338X CXCR4 R338X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 R338X CXCR4 R338X	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 T318fs* CXCR4 T318fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 T318fs* CXCR4 T318fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 L326fs* CXCR4 L326fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 L326fs* CXCR4 L326fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
CXCR4 S347fs* CXCR4 S347fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 S347fs* CXCR4 S347fs*	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials	rituximab + ixazomib Sensitive: C3 – Early Trials
MYD88 L265P + CXCR4 mutation MYD88 L265P + CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 L265P + CXCR4 mutation MYD88 L265P + CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	venetoclax Resistant: C3 – Early Trials	venetoclax Resistant: C3 – Early Trials
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
CD38 expression CD38 expression	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CD38 expression CD38 expression	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials	daratumumab Sensitive: C3 – Early Trials
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials	daratumumab Sensitive: C3 – Early Trials
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials	daratumumab Sensitive: C3 – Early Trials
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib + X4P-001 Sensitive: C3 – Early Trials	ibrutinib + X4P-001 Sensitive: C3 – Early Trials
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	X4P-001 Sensitive: C3 – Early Trials	X4P-001 Sensitive: C3 – Early Trials
CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	CXCR4 mutation CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib + BMS-936564 Sensitive: C3 – Early Trials	ibrutinib + BMS-936564 Sensitive: C3 – Early Trials
MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 L265P MYD88 L265P	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ICP-022 Sensitive: C3 – Early Trials	ICP-022 Sensitive: C3 – Early Trials
MYD88 mutation + CXCR4 mutation MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation + CXCR4 mutation MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib + X4P-001 Sensitive: C3 – Early Trials	ibrutinib + X4P-001 Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab Sensitive: C4 – Case Studies	rituximab Sensitive: C4 – Case Studies

Waldenstrom Macroglobulinemia

Associations(53)

Associations
(53)